Major pharmaceutical companies are ramping up their buying spree of biotech firms this year, driven by the looming threat of losing exclusive rights to their most profitable medications.
Industry data reveals that biotech acquisition deals totaled $84 billion during the first three months of 2026, a significant jump from $44.4 billion during the same period last year. This marks the strongest opening quarter for pharmaceutical mergers and acquisitions since 2019.
The accelerated deal-making stems from what industry experts call the “patent cliff” – a period when pharmaceutical companies lose exclusive marketing rights to their top-selling drugs, opening the door for generic competition.
Among the companies facing this challenge is Merck, whose cancer treatment Keytruda accounts for more than half the company’s total revenue but will lose patent protection in 2028. Other pharmaceutical giants including Eli Lilly, Gilead, Bristol Myers Squibb, and Pfizer are also approaching patent expirations on major revenue-generating medications.
According to Eason Hahm, who directs biopharma investment banking at William Blair, the industry faces potential revenue losses exceeding $300 billion over the next five years due to patent expirations.
“The combination of strategic urgency, tighter private funding, and an uncertain IPO market has created the perfect environment for accelerated dealmaking,” explained Patrice Mesnier, founding partner at investment firm Oldenburg Capital Partners.
Bill Holodnak from advisory firm Occam Global described the situation as companies acting out of “anxiety” regarding their shrinking drug portfolios. “The pharmaceutical industry is always going to have to come to terms with drugs going generic … and if they can’t invent the drugs themselves, they’re going to have to acquire drug candidates on the outside,” Holodnak noted.
Strong financial positions are enabling these acquisition sprees. Eli Lilly, a leader in diabetes and weight-loss medications, finished 2025 with over $7.27 billion in cash reserves and has already spent more than $35 billion on acquisitions through late April.
“Big pharma … do not have the luxury of waiting eight, nine, 10 years to build internal pipelines,” Mesnier observed. “They are no longer buying optionality. They are buying time.”
Leadership changes at companies like GSK and Novo Nordisk have coincided with more aggressive acquisition strategies. Similar shifts in executive roles at Bristol Myers Squibb, Gilead, and AbbVie have also influenced deal negotiations and risk assessment approaches.
If current trends continue, total pharmaceutical merger and acquisition activity could surpass $250 billion for 2026, which would represent the second-highest annual total on record, trailing only 2019’s $328 billion.
Emily Oldshue, a partner at law firm Ropes & Gray who has advised on recent pharmaceutical deals, noted increased activity in mid-sized transactions. “Especially in the sub-$10 billion size range, we are seeing companies risk-on for M&A,” she said. “Companies are placing multiple bets and deploying a variety of structures to hedge and spread risks.”
Cancer treatment development remains the primary focus for acquisition targets, though companies are also showing strong interest in immunology, neurology, heart disease, and obesity treatments. These therapeutic areas offer potential for high-revenue drugs that could offset upcoming patent losses.
Artificial intelligence and machine learning companies focused on drug discovery are emerging as particularly attractive acquisition targets. Mark Kvamme, CEO of the O.H.I.O. Fund investment advisory, believes AI technology will significantly accelerate drug development timelines.
“Because of AI, you’re going to be able to develop these things much more quickly,” Kvamme explained.
Industry analysts from Bernstein noted that the revenue exposure to patent expiration over the next seven years is approximately 2.5 times higher than what the industry experienced over the past 16 years, creating sustained pressure for continued deal-making activity.
